MedTrace Logo

Effect of Brivaracetam in Photosensitive Epileptic Subjects

NCT00401648 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2009-12-01

No results posted yet for this study

Summary

to assess the effect of brivaracetam on the photoparoxysmal EEG response in photosensitive epileptic subjects

Conditions

Interventions

DRUG

Brivaracetam

Sponsors & Collaborators

  • UCB Pharma

    lead INDUSTRY

Principal Investigators

  • Philipp von Rosenstiel, MD. · UCB Pharma

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2002-09-30
Primary Completion
2003-06-30
Completion
2003-06-30

Countries

  • France
  • Germany

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00401648 on ClinicalTrials.gov